中毒性表皮壊死症 (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "中毒性表皮壊死症" in Japanese language version.

refsWebsite
Global rank Japanese rank
2nd place
6th place
4th place
24th place
3,595th place
9,370th place
9,308th place
low place
3,771st place
low place
low place
1,374th place
154th place
11th place
304th place
20th place
222nd place
498th place

doi.org

emedicine.com

genome.gov

nanbyou.or.jp

ndl.go.jp

dl.ndl.go.jp

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Schwartz, RA; McDonough, PH; Lee, BW (August 2013). “Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment.”. Journal of the American Academy of Dermatology 69 (2): 187.e1-16; quiz 203–4. doi:10.1016/j.jaad.2013.05.002. PMID 23866879. 
  • Schwartz, RA; McDonough, PH; Lee, BW (August 2013). “Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis.”. Journal of the American Academy of Dermatology 69 (2): 173.e1-13; quiz 185–6. doi:10.1016/j.jaad.2013.05.003. PMID 23866878. 
  • Bastuji-Garin, S; Rzany, B; Stern, RS; Shear, NH; Naldi, L; Roujeau, JC (January 1993). “Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme.”. Archives of dermatology 129 (1): 92–6. doi:10.1001/archderm.129.1.92. PMID 8420497. 
  • “Erythema multiforme. A heterogeneous pathologic phenotype”. Minerva Stomatol 48 (5): 217–26. (1999). PMID 10434539. 
  • “Mucosal disease series. Number IV. Erythema multiforme”. Oral Dis 11 (5): 261–7. (2005). doi:10.1111/j.1601-0825.2005.01141.x. PMID 16120111. 
  • Jordan, MH; Lewis, MS; Jeng, JG; Rees, JM (1991). “Treatment of toxic epidermal necrolysis by burn units: another market or another threat?”. The Journal of burn care & rehabilitation 12 (6): 579–81. doi:10.1097/00004630-199111000-00015. PMID 1779014. 
  • Roujeau, JC; Stern, RS (10 November 1994). “Severe adverse cutaneous reactions to drugs.”. The New England Journal of Medicine 331 (19): 1272–85. doi:10.1056/nejm199411103311906. PMID 7794310. 
  • Morales, ME; Purdue, GF; Verity, SM; Arnoldo, BD; Blomquist, PH (October 2010). “Ophthalmic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis and Relation to SCORTEN.”. American journal of ophthalmology 150 (4): 505–510.e1. doi:10.1016/j.ajo.2010.04.026. PMID 20619392. 
  • Hung, SI; Chung, WH; Jee, SH; Chen, WC; Chang, YT; Lee, WR; Hu, SL; Wu, MT et al. (April 2006). “Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.”. Pharmacogenetics and genomics 16 (4): 297–306. doi:10.1097/01.fpc.0000199500.46842.4a. PMID 16538176. 
  • McCormack, M; Alfirevic, A; Bourgeois, S; Farrell, JJ; Kasperavičiūtė, D; Carrington, M; Sills, GJ; Marson, T et al. (24 March 2011). “HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.”. The New England Journal of Medicine 364 (12): 1134–43. doi:10.1056/nejmoa1013297. PMID 21428769. 
  • Tohkin, M; Kaniwa, N; Saito, Y; Sugiyama, E; Kurose, K; Nishikawa, J; Hasegawa, R; Aihara, M et al. (February 2013). “A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients.”. The pharmacogenomics journal 13 (1): 60–9. doi:10.1038/tpj.2011.41. PMID 21912425. 
  • Schwartz, RA; McDonough, PH; Lee, BW (Aug 2013). “Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment.”. Journal of the American Academy of Dermatology 69 (2): 187.e1-16; quiz 203–4. doi:10.1016/j.jaad.2013.05.002. PMID 23866879. 
  • Zajicek, R; Pintar, D; Broz, L; Suca, H; Königova, R (May 2012). “Toxic epidermal necrolysis and Stevens-Johnson syndrome at the Prague Burn Centre 1998-2008.”. Journal of the European Academy of Dermatology and Venereology : JEADV 26 (5): 639–43. doi:10.1111/j.1468-3083.2011.04143.x. PMID 21668825. 
  • “Toxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary centre”. Clin. Exp. Dermatol. 35 (8): 853–62. (December 2010). doi:10.1111/j.1365-2230.2010.03826.x. PMID 20456393. http://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0307-6938&date=2010&volume=35&issue=8&spage=853. 
  • Quinn AM; Brown, K; Bonish, BK; Curry, J; Gordon, KB; Sinacore, J; Gamelli, R; Nickoloff, BJ (2005). “Uncovering histological criteria with prognostic significance in toxic epidermal necrolysis”. Arch Dermatol 141 (6): 683–7. doi:10.1001/archderm.141.6.683. PMID 15967913. 
  • Schwartz, RA; McDonough, PH; Lee, BW (August 2013). “Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment.”. Journal of the American Academy of Dermatology 69 (2): 187.e1-16; quiz 203–4. doi:10.1016/j.jaad.2013.05.002. PMID 23866879. 
  • DeMers, G; Meurer, WJ; Shih, R; Rosenbaum, S; Vilke, GM (December 2012). “Tissue plasminogen activator and stroke: review of the literature for the clinician.”. The Journal of emergency medicine 43 (6): 1149–54. doi:10.1016/j.jemermed.2012.05.005. PMID 22818644. 

nii.ac.jp

ci.nii.ac.jp

uptodate.com

wiley.com

onlinelibrary.wiley.com